tiprankstipranks
Advertisement
Advertisement

MNKD Stock Latest News

MannKind price target raised to $14 from $11 at Wells Fargo
The FlyMannKind price target raised to $14 from $11 at Wells Fargo
10h ago
MNKD
MannKind reports ‘positive’ Phase 1b INFLO-1 results
PremiumThe Fly
MannKind reports ‘positive’ Phase 1b INFLO-1 results
1d ago
MNKD
MannKind Raises $50 Million in Private Placement
PremiumCompany Announcements
MannKind Raises $50 Million in Private Placement
6d ago
8K
MNKD
MannKind announces FDA approval of Furoscix ReadyFlow
PremiumThe Fly
MannKind announces FDA approval of Furoscix ReadyFlow
6d ago
MNKD
MannKind announces $50M private placement
PremiumThe Fly
MannKind announces $50M private placement
6d ago
MNKD
MannKind nearing ‘underappreciated catalyst,’ says H.C. Wainwright
PremiumThe FlyMannKind nearing ‘underappreciated catalyst,’ says H.C. Wainwright
7d ago
MNKD
MannKind’s MNKD-201 Trial: A New Inhaled Bet on Idiopathic Pulmonary Fibrosis
Premium
Company Announcements
MannKind’s MNKD-201 Trial: A New Inhaled Bet on Idiopathic Pulmonary Fibrosis
8d ago
MNKD
MannKind’s Inhaled IPF Drug Reaches Key Milestone, Setting Up the Next Move for MNKD
Premium
Company Announcements
MannKind’s Inhaled IPF Drug Reaches Key Milestone, Setting Up the Next Move for MNKD
8d ago
MNKD
MannKind announces milestones in development of nintedanib DPI for IPF
PremiumThe Fly
MannKind announces milestones in development of nintedanib DPI for IPF
2M ago
MNKD
MannKind Gains FDA Approval for Afrezza Pediatric Use
PremiumCompany Announcements
MannKind Gains FDA Approval for Afrezza Pediatric Use
2M ago
8K
MNKD
MannKind price target raised to $11 from $10 at Wells Fargo
PremiumThe Fly
MannKind price target raised to $11 from $10 at Wells Fargo
2M ago
MNKD
MannKind announces FDA approval of Afrezza for use in children aged 6 and older
PremiumThe Fly
MannKind announces FDA approval of Afrezza for use in children aged 6 and older
2M ago
MNKD
MannKind Released From Major Afrezza Trial Obligation
PremiumCompany AnnouncementsMannKind Released From Major Afrezza Trial Obligation
2M ago
8K
MNKD
MannKind Shareholders Reaffirm Board, Pay, and Auditor Roles
Premium
Company Announcements
MannKind Shareholders Reaffirm Board, Pay, and Auditor Roles
2M ago
8K
MNKD
MannKind Leans Into Growth Amid Earnings Volatility
Premium
Company Announcements
MannKind Leans Into Growth Amid Earnings Volatility
3M ago
MNKD
MannKind price target lowered to $7 from $8 at Mizuho
PremiumThe Fly
MannKind price target lowered to $7 from $8 at Mizuho
3M ago
MNKD
MannKind price target raised to $10 from $8 at H.C. Wainwright
PremiumThe Fly
MannKind price target raised to $10 from $8 at H.C. Wainwright
3M ago
MNKD
MannKind price target raised to $10 from $8 at Wells Fargo
PremiumThe Fly
MannKind price target raised to $10 from $8 at Wells Fargo
3M ago
MNKD
MannKind reports Q1 EPS (2c), consensus 1c
PremiumThe Fly
MannKind reports Q1 EPS (2c), consensus 1c
3M ago
MNKD
MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged
PremiumRatingsMannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged
3M ago
MNKD
MNKD Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
MNKD Earnings this Week: How Will it Perform?
3M ago
MNKD
MannKind’s Inhaled Nintedanib Trial: Early IPF Study Moves Forward
Premium
Company Announcements
MannKind’s Inhaled Nintedanib Trial: Early IPF Study Moves Forward
4M ago
MNKD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >